IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. (INAB) on April 28, 2025. The company is a Delaware corporation headquartered in New York, New York, and its common stock trades on The Nasdaq Stock Market LLC. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a Current Report focused on a specific event and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The primary event is the announcement of new preclinical data from the company's innovative gamma-delta T cell engager (γδ-TCE) platform, which was presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
Guidance, Outlook, and Risks
Management commentary is limited to the press release attached as Exhibit 99.1 regarding the preclinical data presentation. The filing does not contain updated financial guidance, specific risk factors, contingencies, or unusual items beyond the scientific update.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for details on the preclinical data presented at the 2025 AACR Annual Meeting.
- Verify the status of the γδ-TCE platform pipeline and potential clinical trial timelines.
- Check subsequent filings (e.g., 10-Q or 10-K) for the most recent financial position, cash runway, and burn rate.
- Confirm the company's emerging growth company status and any related accounting election impacts.